SecBot SecBot
SECBOTREPLAY Home › Report › MNKD

MNKD · MannKind announced nine poster presentations at ADA 2026 covering…

MannKind · PRESS-RELEASE filed May 27, 2026 at 09:05 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 27, 2026 at 09:05 ET

MannKind announced nine poster presentations at ADA 2026 covering Afrezza data in pediatric efficacy, treatment satisfaction, AID algorithm use, and gestational diabetes. The PDUFA target action date for Afrezza in pediatric patients (ages 4-17) is May 29, 2026, just two days after this press release. The data broadly support Afrezza's profile but the key catalyst is the upcoming FDA decision on pediatric approval.

  • PDUFA target action date for Afrezza pediatric indication (ages 4-17) is May 29, 2026
  • Nine poster presentations at ADA 2026 (June 5-8) including pediatric A1c, treatment satisfaction, AID algorithm, and gestational diabetes data
  • If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over 100 years
  • FDA accepted sBLA for review in October 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access